Figure 5

GCDA reverses irinotecan-induced downregulation of pERK and Mcl-1 and enhances survival. (A) and (B) HepG2 cells were treated with irinotecan in the absence or presence of GCDA for 24 h. The pERK, total ERK1/2 and Mcl-1 were analyzed by Western blot. (C) HepG2 cells were treated with irinotecan in the absence or presence of GCDA for 24 h. Cell viability was determined by analyzing annexin-V binding by FACS. Data represent the mean ± S.D. of three separate determinations.